<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308049">
  <stage>Registered</stage>
  <submitdate>10/06/2009</submitdate>
  <approvaldate>18/06/2009</approvaldate>
  <actrnumber>ACTRN12609000486224</actrnumber>
  <trial_identification>
    <studytitle>Effect of vitamin D supplementation on upper respiratory infections in adults</studytitle>
    <scientifictitle>In healthy adults, is vitamin D supplementation better than placebo for preventing and/or reducing the severity of upper respiratory tract infections?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HRC 09/302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Upper respiratory tract infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Vitamin D3 200,000 IU oral tablet at baseline, then 200,000 IU oral tablet one month later, then 100,000 IU oral tablet monthly for 18 months.</interventions>
    <comparator>Placebo (matching sugar pill) - 335 mg oral tablets taken monthly for 18 months starting 1 month after initial loading doses at baseline and 1 month later.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence rate of upper respiratory tract infections as assessed by questionnaires.</outcome>
      <timepoint>18 months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of upper respiratory tract infections (mean sum of Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) scores over 7 days from the onset of symptoms)</outcome>
      <timepoint>18 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of days off work due to upper respiratory tract infections as assessed by questionnaires.</outcome>
      <timepoint>18 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resting bood pressure, measured in a seated position with an automatic shygmomanometer</outcome>
      <timepoint>Baseline, 5 months and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Staphylococcus aureus nasal carriage by culture of nasal swabs.</outcome>
      <timepoint>Baseline, 6 months, 12 months and 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dandruff/dry scalp by participant reports.</outcome>
      <timepoint>Baseline and 5 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age 18 years and over, ability to give informed consent, anticipated residence in Christchurch for the 18-month study period</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Use of vitamin D3 supplements, pregnancy, use of immunosuppressants or medications that interfere with vitamin D metabolism, history of hypercalcaemia, nephrolithiasis or sarcoidosis, and current kidney or liver disorders, malignancy and malabsorption.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>22/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>320</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>P.O. Box 4345, Christchurch 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>Level 3, 110 Stanley Street, Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland</sponsorname>
      <sponsoraddress>P.O. Box 92019, Auckland 1142</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Canterbury Health Laboratories</othercollaboratorname>
      <othercollaboratoraddress>P.O. Box 151, Christchurch 8011</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main hypothesis of the study is that maintaining an adequate vitamin D level will prevent and/or reduce the severity of upper respiratory infections.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>30/06/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Murdoch</name>
      <address>University of Otago, Christchurch
P.O. Box 4345
Christchurch 8140</address>
      <phone>+64 3 364 0590</phone>
      <fax />
      <email>david.murdoch@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Murdoch</name>
      <address>University of Otago, Christchurch
P.O. Box 4345
Christchurch 8140</address>
      <phone>+64 3 364 0590</phone>
      <fax />
      <email>david.murdoch@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>